financetom
Business
financetom
/
Business
/
RH Likely to Miss Existing Financial Outlook, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RH Likely to Miss Existing Financial Outlook, UBS Says
Sep 6, 2024 12:51 PM

03:32 PM EDT, 09/06/2024 (MT Newswires) -- RH's (RH) has shown some improvement in terms of demand in Q2, but is unlikely to meet its existing outlook, UBS Securities said in a note emailed Friday.

"In this case, the company is likely to lower its prior guidance that called for a significant inflection in its business in the back half of this year," UBS said.The market is looking at potential earnings per share growth for 2025 and 2026, but these gains might start from a lower base and continued use of promotions could affect long-term margins.

Industry trends suggest weak demand, with peers like Williams-Sonoma's ( WSM ) and Wayfair ( W ) lowering forecasts, "this suggests RH may need to push out its expectation for a meaningful revenue inflection yet again," UBS said.

UBS has neutral rating on RH and maintained its price target of $280, based on a lower multiple reflecting a more normalized market scenario.

Price: 250.43, Change: +0.60, Percent Change: +0.24

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Privia Health Group Adjusted Earnings, Revenue Rise in Q1; Offers Full Year 2024 Revenue Guidance
Privia Health Group Adjusted Earnings, Revenue Rise in Q1; Offers Full Year 2024 Revenue Guidance
May 9, 2024
07:00 AM EDT, 05/09/2024 (MT Newswires) -- Privia Health Group ( PRVA ) reported Q1 earnings Thursday of $0.18 per share, up from $0.16 a year earlier. Analysts polled by Capital IQ expected $0.15. Revenue for the quarter ended March 31 was $415.2 million, up from $386.3 million a year earlier. Analysts surveyed by Capital IQ expected $394.8 million. The...
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
May 9, 2024
May 9 (Reuters) - Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management. (Reporting by Puyaan Singh in Benagluru; Editing by Anil D'Silva) ...
Merck's endometrial cancer therapy fails trial
Merck's endometrial cancer therapy fails trial
May 9, 2024
May 9 (Reuters) - Merck ( MRK ) said on Thursday its therapy did not meet the main goal of disease-free survival in certain patients with endometrial cancer during a late-stage trial. The drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in patients with high-risk endometrial cancer after surgery. The study's other main goal of overall survival was...
Warner Bros Discovery misses estimates for quarterly revenue
Warner Bros Discovery misses estimates for quarterly revenue
May 9, 2024
(Reuters) -Warner Bros Discovery ( WBD ) missed Wall Street estimates for first-quarter revenue on Thursday, weighed down by a weak advertising market and strike-related delays at its studio segment. Shares of the company were down 1.9% in premarket trading. Subdued advertising trends in the U.S. and certain international markets amid concerns over higher-for-longer interest rate environment have posed challenges...
Copyright 2023-2026 - www.financetom.com All Rights Reserved